425 related articles for article (PubMed ID: 31834327)
1. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
Eto Y; Saubi N; Ferrer P; Joseph J
AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
[TBL] [Abstract][Full Text] [Related]
2. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
3. Papillomavirus-like particle vaccines.
Schiller JT; Lowy DR
J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
[TBL] [Abstract][Full Text] [Related]
4. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
[TBL] [Abstract][Full Text] [Related]
5. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
Yadav R; Zhai L; Tumban E
Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
[TBL] [Abstract][Full Text] [Related]
6. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
[TBL] [Abstract][Full Text] [Related]
7. Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.
Berg MG; Adams RJ; Gambhira R; Siracusa MC; Scott AL; Roden RB; Ketner G
Clin Vaccine Immunol; 2014 Sep; 21(9):1224-31. PubMed ID: 24990902
[TBL] [Abstract][Full Text] [Related]
8. Virus-like particles for the prevention of human papillomavirus-associated malignancies.
Wang JW; Roden RB
Expert Rev Vaccines; 2013 Feb; 12(2):129-41. PubMed ID: 23414405
[TBL] [Abstract][Full Text] [Related]
9. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
10. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
11. Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51.
Yadav R; Zhai L; Kunda NK; Muttil P; Tumban E
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200586
[TBL] [Abstract][Full Text] [Related]
12. Major findings and recent advances in virus-like particle (VLP)-based vaccines.
Mohsen MO; Zha L; Cabral-Miranda G; Bachmann MF
Semin Immunol; 2017 Dec; 34():123-132. PubMed ID: 28887001
[TBL] [Abstract][Full Text] [Related]
13. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
Bolhassani A; Shirbaghaee Z; Agi E; Davoudi N
Protein Expr Purif; 2015 Dec; 116():7-11. PubMed ID: 26304732
[TBL] [Abstract][Full Text] [Related]
14. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
[TBL] [Abstract][Full Text] [Related]
15. Virus-like Particle Vaccines and Platforms for Vaccine Development.
Kheirvari M; Liu H; Tumban E
Viruses; 2023 May; 15(5):. PubMed ID: 37243195
[TBL] [Abstract][Full Text] [Related]
16. Construction and Production of HIV-VLP Harboring MPER-V3 for Potential Vaccine Study.
Tohidi F; Sadat SM; Bolhassani A; Yaghobi R
Curr HIV Res; 2017; 15(6):434-439. PubMed ID: 29046160
[TBL] [Abstract][Full Text] [Related]
17. Developments in virus-like particle-based vaccines for HIV.
Buonaguro L; Tagliamonte M; Visciano ML; Tornesello ML; Buonaguro FM
Expert Rev Vaccines; 2013 Feb; 12(2):119-27. PubMed ID: 23414404
[TBL] [Abstract][Full Text] [Related]
18. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.
Diamos AG; Larios D; Brown L; Kilbourne J; Kim HS; Saxena D; Palmer KE; Mason HS
Vaccine; 2019 Jan; 37(1):137-144. PubMed ID: 30459071
[TBL] [Abstract][Full Text] [Related]
19. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions.
Chen J; Ni G; Liu XS
Cell Immunol; 2011; 269(1):5-9. PubMed ID: 21477796
[TBL] [Abstract][Full Text] [Related]
20. Virus-like particles: potential veterinary vaccine immunogens.
Liu F; Ge S; Li L; Wu X; Liu Z; Wang Z
Res Vet Sci; 2012 Oct; 93(2):553-9. PubMed ID: 22100244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
